107P Health-related quality of life with ivonescimab versus pembrolizumab for PD-L1 positive, non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase III study in China
In HARMONi-2 study, ivonescimab significantly improved progression free survival (PFS) compared with pembrolizumab in previously untreated patients with advanced PD-L1 positive non-small cell lung cancer (NSCLC), with manageable safety profile. Here we reported health-related quality of life (HRQoL) from HARMONi-2.
Authors
- W Li
- G. Li
- J. Li
- C. Zhou
- Z. Han
- Y. Sun
- B. Liu
- J. Yao
- Q. Bu
- M. Zhou
- Y. Zhao
- H. Ge
- J. Wang
- S. Zhang
- Y.M. Xia
- Q. Shi
- H. Zhong
Institutions
- Hebei Medical University (CN)
- Harbin Medical University (CN)
- Guangxi Medical University (CN)
- Xuzhou Medical College (CN)
- Kunming Medical University (CN)
- Shanghai Chest Hospital (CN)
- Chinese PLA General Hospital (CN)
- 307th Hospital of Chinese People’s Liberation Army (CN)
- Jilin Province Tumor Hospital (CN)
- Shandong Tumor Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Jiangsu T-mab BioPharma (China) (CN)
- Fuzhou Dermatosis Prevention Hospital (CN)
- Fuzhou Pulmonary Hospital of Fujian (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Shanghai Pulmonary Hospital (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- Henan Cancer Hospital (CN)
- Chinese People's Liberation Army (CN)
- Shandong First Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106414
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00